Supplement Industry Embraces GLP-1

This is a news story, published by Wired, that relates primarily to Supergut news.

Supergut news

For more Supergut news, you can click here:

more Supergut news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Wired news

For more news from Wired, you can click here:

more news from Wired

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

loss supplements

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest market supplements news, alternative supplement purveyors news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

loss supplement

Wired

•

Supplements Companies Are Cashing In on the Ozempic Wave

Summary

Nutrition label

62% Informative

More than 15 percent of adult Americans have tried a weight-loss supplement.

GLP-1 agonist drugs like semaglutide and tirzepatide mimic a natural appetite-suppressing, blood-sugar-regulating hormone called glucagon-like peptide-1.

The supplement industry has a long, tangled history with the world of diet aids.

Alternative GLP-1 supplements face skepticism about their claims.

Some health experts question whether these offerings are worthwhile.

The FDA cannot force supplement-makers to conduct premarket testing to demonstrate that their products contain what they say they contain.

The regulatory environment is often described as a wild west.

Supergut ran its own double-blind, placebo-controlled clinical trial, which is not yet common in this corner of the industry.

It found that taking the prebiotic shakes helped regulate blood sugar better than placebos in the study participants.

But experts are skeptical about the new category of supplements sold with “ GLP-1 ” branding.

VR Score

Informative language

Neutral language

Article tone